Trial Profile

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Antineoplastics
Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Registrational; Therapeutic Use
Acronyms eMonarcHER
Sponsors Eli Lilly and Company

25 Jul 2024 Status changed from active, no longer recruiting to discontinued.(Reason the study was stopped: Study is terminated due to inability to enroll study participants).
19 Jun 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
21 May 2024 This trial has been completed in France, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com